Aclarion (ACON) Competitors $7.50 -0.18 (-2.34%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$7.50 0.00 (-0.07%) As of 07/3/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ACON vs. ENZ, BRTX, MGRX, SSY, BGLC, VSEE, ATIP, DHAC, OTRK, and NIVFShould you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include Enzo Biochem (ENZ), Biorestorative Therapies (BRTX), Mangoceuticals (MGRX), SunLink Health Systems (SSY), BioNexus Gene Lab (BGLC), VSee Health (VSEE), ATI Physical Therapy (ATIP), Digital Health Acquisition (DHAC), Ontrak (OTRK), and NewGenIvf Group (NIVF). These companies are all part of the "healthcare" industry. Aclarion vs. Its Competitors Enzo Biochem Biorestorative Therapies Mangoceuticals SunLink Health Systems BioNexus Gene Lab VSee Health ATI Physical Therapy Digital Health Acquisition Ontrak NewGenIvf Group Enzo Biochem (NYSE:ENZ) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Does the media prefer ENZ or ACON? In the previous week, Aclarion had 1 more articles in the media than Enzo Biochem. MarketBeat recorded 1 mentions for Aclarion and 0 mentions for Enzo Biochem. Aclarion's average media sentiment score of 0.59 beat Enzo Biochem's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media. Company Overall Sentiment Enzo Biochem Neutral Aclarion Positive Do analysts rate ENZ or ACON? Aclarion has a consensus target price of $11,758.50, indicating a potential upside of 156,680.00%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Enzo Biochem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enzo Biochem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aclarion 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, ENZ or ACON? Enzo Biochem has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Is ENZ or ACON more profitable? Enzo Biochem has a net margin of -75.34% compared to Aclarion's net margin of -12,227.10%. Enzo Biochem's return on equity of -7.96% beat Aclarion's return on equity.Company Net Margins Return on Equity Return on Assets Enzo Biochem-75.34% -7.96% -5.49% Aclarion -12,227.10%-126.89%-106.61% Which has stronger valuation & earnings, ENZ or ACON? Aclarion has lower revenue, but higher earnings than Enzo Biochem. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnzo Biochem$29.09M0.59-$26.08MN/AN/AAclarion$50K87.00-$6.99MN/AN/A Do institutionals & insiders believe in ENZ or ACON? 36.9% of Enzo Biochem shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 11.4% of Enzo Biochem shares are owned by company insiders. Comparatively, 0.8% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryAclarion beats Enzo Biochem on 7 of the 13 factors compared between the two stocks. Get Aclarion News Delivered to You Automatically Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACON vs. The Competition Export to ExcelMetricAclarionMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.35M$7.31B$5.53B$9.02BDividend YieldN/A2.78%5.22%3.99%P/E RatioN/A27.9427.7020.25Price / Sales87.0032.39419.56119.26Price / CashN/A20.3926.2128.59Price / Book0.156.698.035.65Net Income-$6.99M$233.06M$3.18B$249.15M7 Day Performance-0.40%2.51%2.88%2.91%1 Month Performance9.17%1.79%1.67%4.11%1 Year Performance-99.71%37.40%34.39%20.98% Aclarion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACONAclarion2.2648 of 5 stars$7.50-2.3%$11,758.50+156,680.0%-99.7%$4.35M$50K0.007ENZEnzo BiochemN/A$0.33-14.8%N/A-69.3%$17.03M$29.09M0.00520Gap DownHigh Trading VolumeBRTXBiorestorative Therapies2.7439 of 5 stars$1.67+3.5%$18.00+980.7%-15.3%$12.49M$400K-1.137MGRXMangoceuticals0.8373 of 5 stars$1.52-12.1%N/A-97.8%$7.86M$620K-0.333Positive NewsGap DownSSYSunLink Health SystemsN/A$0.88+0.6%N/A+10.7%$6.20M$31.09M6.291,376BGLCBioNexus Gene Lab0.4104 of 5 stars$3.07+10.8%N/A+36.0%$5.53M$9.51M0.0030Gap DownVSEEVSee Health1.1861 of 5 stars$1.16+5.5%$5.00+331.0%N/A$4.18MN/A0.00N/AGap UpATIPATI Physical Therapy0.1948 of 5 stars$0.90+4.7%N/A-80.2%$3.97M$741.86M-0.055,600Gap DownDHACDigital Health AcquisitionN/A$1.10-3.5%N/A-86.8%$3.96MN/A0.002,021Gap DownOTRKOntrak2.8838 of 5 stars$0.50-9.8%$45.00+8,916.2%-84.1%$2.11M$10.85M-0.03250High Trading VolumeNIVFNewGenIvf GroupN/A$1.04+1.0%N/A-99.5%$543K$5.43M0.00N/AGap DownHigh Trading Volume Related Companies and Tools Related Companies Enzo Biochem Competitors Biorestorative Therapies Competitors Mangoceuticals Competitors SunLink Health Systems Competitors BioNexus Gene Lab Competitors VSee Health Competitors ATI Physical Therapy Competitors Digital Health Acquisition Competitors Ontrak Competitors NewGenIvf Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACON) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclarion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
